ERT, a global data and technology company that minimises risk and uncertainty in clinical trials, has announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year Award.
ERT is one of only three companies nominated to receive this recognition.
Every year, the PACT Enterprise Awards Programme recognises and honours leadership and outstanding achievement in the technology, healthcare and life sciences industries throughout the region.
ERT has been selected for its impact in improving and accelerating new pharmaceutical product development, specifically for delivering critical safety and efficacy data that supported more than 50% of all FDA new drug approvals for over 45 years.
“ERT deserves to be celebrated for their achievements and contributions to advancing the technology, healthcare and life sciences industries throughout the region,” said Dianne Strunk, Vice President, PACT. “We are pleased to recognise ERT as they truly embody an innovative spirit and represent the future of the region’s economy.”
“We are proud to be recognised as a PACT Technology Company Award finalist and to be considered one of Philadelphia’s leading life science companies,” said James Corrigan, President and CEO of ERT. “This recognition is a reflection of our employees’ unwavering commitment to delivering innovative and practical solutions that our customers can have confidence in as they bring life-changing medical treatments to the patients who need them.”
Powered by ERT’s EXPERT technology platform, ERT’s eClinical solutions have been used in 9,500+ clinical trials supporting 3 million patients to date, helping to improve trial visibility and performance while reducing time to market.
For more information, visit www.ert.com.
